Volume 29, Number 8—August 2023
Synopsis
Response to Vaccine-Derived Polioviruses Detected through Environmental Surveillance, Guatemala, 2019
Table 2
Year | Dose | Villa Nueva |
San Juan Sacatepequez |
National |
|||||
---|---|---|---|---|---|---|---|---|---|
Population | No. (%) vaccinated | Population | No. (%) vaccinated | Population | No. (%) vaccinated | ||||
2017 | Polio 3 | 8,339 | 6,282 (75.3) | 6,159 | 3,824 (62.1) | 381,396 | 342,437 (89.8) | ||
2018 | Polio 3 | 8,296 | 6,055 (73.0) | 6,141 | 3,942 (64.2) | 382,841 | 324,761 (84.8) | ||
2019 | Polio 3 | 7,252 | 5,495 (75.8) | 5,856 | 4,056 (69.3) | 366,448 | 320,963 (87.6) | ||
2020 | Polio 3 | 6,671 | 5,570 (83.5) | 5,513 | 4,252 (77.1) | 340,876 | 304,898 (89.4) | ||
2019 | bOPV | 57,979 | 54,942 (94.8) | 41,639 | 37,969 (91.2) | 2,649,334 | 2,463,881 (93.0) |
*The 2019 nationwide bOPV campaign targeted children 6 mo to <7 y of age. Polio 3 indicates a third dose of oral or injectable polio-containing vaccine. bOPV, bivalent oral poliovirus vaccine. Source: National Immunization Program, Guatemala Ministry of Health.
1These first authors contributed equally to this article.
Page created: June 14, 2023
Page updated: July 20, 2023
Page reviewed: July 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.